TREE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LendingTree Inc (TREE) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown strong financial performance in the latest quarter and analysts maintain positive ratings, insider selling, lack of significant hedge fund activity, and no strong trading signals suggest waiting for better entry points. Additionally, the stock's technical indicators and options data do not indicate a compelling immediate opportunity.
The MACD histogram is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 57.773, and moving averages are converging, showing no clear trend. Key support is at 42.104, and resistance is at 49.928. The stock is trading near its pivot point of 46.016, suggesting limited immediate upside potential.
The company's Q4 2025 financials showed significant growth, with revenue up 22.24% YoY, net income up 1827.20% YoY, and EPS up 1655.36% YoY. Analysts have maintained positive ratings with price targets ranging from $50 to $76, citing strong performance in the insurance segment and diversified revenue base.
Insiders have significantly increased selling activity (up 1220.79% over the last month), and hedge funds are neutral with no significant trading trends. The stock is trading near a 10-year trough adjusted EBITDA multiple, and AI poses a potential long-term risk to the company's business model. Additionally, no recent congressional trading data or strong proprietary trading signals are present.
In Q4 2025, LendingTree reported strong financial growth: Revenue increased to $319.69M (+22.24% YoY), net income surged to $144.66M (+1827.20% YoY), EPS rose to 9.83 (+1655.36% YoY), and gross margin improved to 94.75% (+0.79% YoY).
Analysts maintain positive ratings with price targets ranging from $50 to $76. JPMorgan recently assumed coverage with an Overweight rating and a price target of $50, citing the stock's low valuation and role in the financial product value chain. Other analysts highlight strong Q4 results and insurance segment momentum but have lowered price targets due to sector-wide valuation compression.
